Glycoengineering of Interferon-β 1a improves its biophysical and pharmacokinetic properties

Citations of this article
Mendeley users who have this article in their library.


The purpose of this study was to develop a biobetter version of recombinant human interferon-β 1a (rhIFN-β 1a) to improve its biophysical properties, such as aggregation, production and stability, and pharmacokinetic properties without jeopardizing its activity. To achieve this, we introduced additional glycosylation into rhIFN-β 1a via site-directed mutagenesis. Glycoengineering of rhIFN-β 1a resulted in a new molecular entity, termed R27T, which was defined as a rhIFN-β mutein with two N-glycosylation sites at 80th(original site) and at an additional 25thamino acid due to a mutation of Thr for Arg at position 27thof rhIFN-β 1a. Glycoengineering had no effect on rhIFN-β ligand-receptor binding, as no loss of specific activity was observed. R27T showed improved stability and had a reduced propensity for aggregation and an increased half-life. Therefore, hyperglycosylated rhIFN-β could be a biobetter version of rhIFN-β1a with a potential for use as a drug against multiple sclerosis. © 2014 Song et al.




Song, K., Yoon, I. S., Kim, N. A., Kim, D. H., Lee, J., Lee, H. J., … Shin, Y. K. (2014). Glycoengineering of Interferon-β 1a improves its biophysical and pharmacokinetic properties. PLoS ONE, 9(5).

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free